US Pharma MarketingThe post AstraZeneca axes NSCLC trial after bispecific deemed unlikely to best Keytruda appeared first on Clinical Trials Arena.
AstraZeneca axes NSCLC trial after bispecific deemed unlikely to best Keytruda
While it discontinued the Phase III trial, AstraZeneca did announce two NSCLC successes with other oncology assets. The post AstraZeneca axes NSCLC trial after bispecific deemed unlikely to best Keytruda appeared first on Clinical Trials Arena .
While it discontinued the Phase III trial, AstraZeneca did announce two NSCLC successes with other oncology assets.
Source: Clinical Trials Arena